Safety and immunogenicity of a 4-component GMMA-based Shigella vaccine in healthy European adults: Stage 1 of a randomized, controlled phase I/II clinical trial.
Isabel Leroux-RoelsCathy MaesFrancesca ManciniBart JacobsEleanna SarakinouAzhar AlhatemiJasper JoyeSilvia GrappiGiulia Luna CilioAlimamy Serry-BanguraClaudia G VitaliPietro FerruzziElisa MarchettiFrancesca NecchiRino RappuoliIris De RyckJochen AuerbachAnna M ColucciOmar RossiValentino ContiFrancesco Berlanda ScorzaAshwani Kumar AroraFrancesca MicoliAudino PoddaUsman Nasir Nakakananull nullPublished in: The Journal of infectious diseases (2024)
No safety signals or concerns were identified. altSonflex1-2-3 induced functional serotype-specific immune responses, allowing further clinical development in the target population.